NOW vs PFE: Which Is the Better Buy?
Side-by-side comparison of ServiceNow, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-09-18.
ServiceNow, Inc. · Technology
$139.82
+16.2% upside to fair value
Med Conviction
Grade A-
High Quality
VS
Pfizer Inc. · Healthcare
$27.64
+12.0% upside to fair value
Med Conviction
Grade B
QuantHub Verdict
NOW has more upside to fair value
(+16.2%).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
NOW |
PFE |
| Current Price |
$139.82 |
$27.64 |
| Fair Value Estimate |
$162.50 |
$30.94 |
| Upside to Fair Value |
+16.2%
|
+12.0%
|
| Market Cap |
$144.6B |
$157.5B |
| Forward P/E |
—
|
—
|
| EV / EBITDA |
43.1x
|
17.4x
|
| Price / Sales |
9.8x
|
2.5x
|
| Price / FCF |
31.5x
|
14.3x
|
| Revenue Growth YoY |
+24.0%
|
+2.6%
|
| Gross Margin |
74.8%
|
71.3%
|
| Operating Margin |
11.4%
|
25.1%
|
| Return on Equity |
13.8%
|
4.9%
|
| Dividend Yield |
0% |
6.22% |
| FCF Yield |
3.17%
|
6.97%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
ServiceNow provides a cloud-based enterprise workflow platform spanning IT service management, operations, employee workflows, CRM, AI orchestration and security. Business quality is high because its common data model, deeply embedded workflows and cross-department deployments create meaningful switching costs, while roughly 90% of the Fortune 500 use the platform and more than 85 billion workflo…
Pfizer is a global biopharmaceutical leader with a portfolio spanning cardiovascular, oncology, vaccines, immunology, and rare disease, anchored by Eliquis, the Prevnar family, Vyndaqel, Ibrance, Xtandi, Comirnaty, and Paxlovid, and supported by roughly 75,000 employees and a contract manufacturing division. Business quality is medium rather than high: TTM gross margin of 71.3% and TTM operating …
Accumulation Zones
| Metric |
NOW |
PFE |
| Zone Low |
$121.88 |
$23.21 |
| Zone High |
$138.12 |
$26.30 |
| In Buy Zone? |
No
|
No
|